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Summary: This study was designed to analyze the cross-sectional comparison of the
p16INK4A and Ki-67 immunocytochemical expression in negative and equivocal (atyp-
ical squamous cells of undetermined significance (ASC-US)) liquid-based cytology
(LBC) samples testing positive for high-risk human papillomavirus (HPV) types with
HC2 assay or polymerase-chain reaction (PCR). A series of 199 consecutive LBC speci-
mens derived from the same number of women participating in the ongoing Latin Amer-
ican Screening Study at Leonor Mendes de Barros Hospital, Sa˜o Paulo, were analyzed
using immunocytochemistry for expression of p16INK4A and Ki-67 in negative and
equivocal LBC samples testing positive for high-risk HPV types with hybrid capture
II test (HC2) or PCR. All patients with at least one test positive (cytology, PCR, and/or
HC2) were followed each 6 months for 3 years. The follow-up procedure consisted of
visual examination, colposcopic inspection, cytology, and HC2 assay. Among the neg-
ative cytologic samples, 101 were HPV-positive and 55 HPV-negative. Of the HPV-pos-
itive group, 59 of 101 cases (58.4%) were positive for both p16 and Ki67
immunostaining, and 17 of 101 (16.8%) were negative for both. The proportion of
Ki-67-positivity increased almost in parallel with the increasing grade of p16-positivity
(p = 0.0001 for linear trend). In the HPV-negative group, both markers were negative in
41 of 55 cases (74.5%), and no statistical relationship was observed between the two
markers (Pearson, p = 0.595). HPV-positive ASC-US samples demonstrated a simulta-
neous positive immunoreaction for p16 and Ki67 in 11 of 16 cases (68.7%), whereas 3
(18.7%) were concurrently negative. The relationship between the two markers was of
borderline significance (Pearson, p = 0.053), but no linear relationship was found be-
tween the graded p16 and Ki-67 expression (p = 0.065 for linear trend). In the HPV-
negative ASC-US group, there was no statistical association between the graded p16
and Ki-67 positivity (Pearson, p = 0.281). After 36 months of follow-up of the ASC-US
patients, 6 women still displayed ASC-US smear, of which 4 of 6 were HPV-positive
and expressed both p16 and Ki-67 markers. Two of 43 ASC-US smears had high-grade
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squamous intraepithelial lesions diagnosed (4.6%), and 1 had low-grade squamous
intraepithelial lesion (2.3%). All of those were positive for HPV, p16 and Ki-67. Patients
with ASC-US diagnosis and positive high-risk HPV status and positive for p16INK4A
Ki67 should be carefully observed to exclude occurrence of a squamous intraepithelial
lesion. The combination of these two markers can be a useful implement for manage-
ment of women with equivocal cytology. KeyWords: p16—Ki67—Cervical cancer—
Human papillomavirus—Liquid-based cytology.
Persistent high-risk human papillomavirus (HPV) in-
fection is probably the best predictor of increased risk
for cervical cancer (1). The presence of HPV is an essen-
tial but not-sufficient cause of cervical cancer (2). Recent
molecular biology data on the natural history of HPV in-
fections and cervical cancer suggest that the viral infec-
tion critically interferes with the mechanisms of cellular
growth, DNA repair, and immunologic responses (2). Part
of these interferences is related to the action of oncopro-
teins encoded by E6 and E7 HPV genes that bind in the
regulatory proteins of the cells, including those of p53
and RB-suppressor genes (3).
The protein p16 is a product of CDKN2A gene that
suppresses the activity of CDK-4 and -6 cyclins, which
regulates the G1 checkpoint (3). The p16 protein seems
to interfere with the transforming activity of E6 but E7
interaction with RB can directly stimulates the cyclins
inducing cell replication. The p16 is overexpressed, but
its function is seriously affected as a consequence of
the inactivation of suppressor proteins (4). For this rea-
son, the overexpression of p16 protein is associated with
the oncogenic potential of papillomaviruses in cervical
and genital lesions (3,5). Moreover, p16 also is presumed
to be a molecular biomarker for high-risk HVP in malig-
nant and premalignant lesions of the vulva (6), squamous
cell carcinoma of the anorectal region (7), penile carci-
noma (8), and oral lesions (9). Additionally, p16 is over-
expressed in cervical adenocarcinoma (both in situ
and invasive) (10,11), and it is recognized as a strong
predictor of poor prognosis in these lesions (12). Recent-
ly, immunohistochemical (IHC) expression of p16 has
been used to discriminate cervical from endometrial
adenocarcinomas if accompanied by high-risk HPV
types (13).
Ki-67 expression in early intraepithelial lesions is a
strong predictor of progression (14). Expression of Ki-67
seems to increase progressively in parallel with the increas-
ing aggressiveness of the lesions (15). However, Ki-67 is
not an independent prognostic predictor (16).
Screening by cervical cytology suffers from inherent
problems in sensitivity, and more recently, auxiliary tech-
niques have been proposed to improve the performance of
cervical cytology. Hybrid Capture II (HC2), used to de-
tect high-risk HPV, seems to represent a remarkable im-
provement for cervical cancer screening, particularly in
triaging equivocal cytological diagnoses (17). Because
only persistent HPV infections can progress to carcino-
ma (1), different combinations of p16 overexpression,
Ki-67 status, and HPV testing have been implicated as
potential markers to predict the behavior of both glandu-
lar and squamous lesions of the cervix (5,18–20). Fur-
thermore, the use of p16 and Ki-67 has been suggested
as a useful tool in assessing the true nature of cytologic
smears classified as atypical squamous cells of undeter-
mined significance (ASC-US) (20,21).
This study was designed to analyze the cross-sectional
comparison of the p16INK4A and Ki-67 immunocyto-
chemical expression in negative and equivocal (ASC-US)
liquid-based cytology (LBC) samples testing positive
for high-risk HPV types with HC2 assay or polymerase-
chain reaction (PCR).
MATERIALS AND METHODS
The present series comprised 199 (6.63%) from 3,000
consecutive women participating in the ongoing Latin
American Screening (LAMS) Study, and attending Leonor
Mendes de Barros Hospital, Sa˜o Paulo, from 2002 to
2004. The women were eligible for the study if no pre-
vious history of HPV infection or any other cervical pa-
thology was reported. The mean age of the women was 37
(range, 18–55) years. The patients had been sampled for
LBC and subjected to HPV testing with HC2 assay (high-
risk HPV types) at their first clinical visit. In addition,
a multiplex PCR for HPV was performed in the residual
LBC medium. The ethics committee of the hospital ap-
proved the project.
For this study we selected from the 3,000 patients, slides
from 156 (5,2%) patients cytologically negative, and 43
(1.43%) classified as ASC-US in whom HPV-positive or
-negative status were available by PCR and/or HC2 assay.
All patients with at least one test positive (cytology,
PCR, and/orHC2) were followed every 6 months for
119p16 AND ONCOGENIC HPV
Int J Gynecol Pathol, Vol. 24, No. 2, April 2005
3 years. The follow-up procedure has consisted of visual
examination, colposcopic inspection, cytology, and HC2
assay.
Cytologic Samples
Cervical samples were collected with a scored cervi-
cal brush included in the manual DNACitoliq (Digene
Brasil, Sa˜o Paulo, Brazil) LBC system and stored in Uni-
versal Collection Medium. Details of the preparation of
the slides were reported recently (22). The classification
of cytology was performed according to the Bethesda 2001
system (23). The final cytological diagnoses were con-
firmed by consensus of two independent cytopathologists.
Immunocytochemistry for p16 and Ki-67
Immunocytochemical (ICC) analysis was performed
directly on slides with LBC smears previously stained
with Papanicolaou technique. Only the slides with a suf-
ficient amount of cells were subjected to ICC analysis.
The ICC procedures were performed after removing cov-
erslips from the slides in xylene and rehydrating smears
in decreasing concentrations of ethyl alcohol and in dis-
tilled water. Antigen retrieval was performed using a 10-mM
concentration of citrate buffer (pH 6.0) in a pressure
cooker for 4 minutes. The slides were allowed to cool un-
til room temperature and were then subjected to immuno-
staining. The antibodies used in this study were p16INK4A
(diluted 1:500), obtained from MTM Lab AG (Germany),
and the Ki-67 antigen (diluted 1:100), supplied by Dako
AS (Denmark), both amplified by labeled streptavidin-
biotin-peroxidase system obtained from Dako Cytomation.
The color of immunostaining was developed by chromo-
genic substrate diaminobenzidine (100 mg%) and hydro-
gen peroxide (0.1%). After light counterstaining in Harry’s
hematoxylin, the slides were mounted and analyzed using
light microscopy.
Evaluation of the ICC Staining
Evaluation of the ICC staining was performed count-
ing the positive reactions in 1,000 cells at magnification
of 3400. All positive cells were counted in whole slide
(DNA-Citoliq System slide, with 2.5 cm of diameter of
cell area). The p16 reaction was evaluated as positive if
nuclear or cytoplasmic immunostaining was clearly dem-
onstrated. For Ki-67, only nuclear reaction was consid-
ered positive. Positive immunostaining (per 1,000 cells)
was graded as follows: negative (0); faintly positive, if be-
tween ‡1 and £10 cells stained; sporadic if >10 and £50;
intermediate >50 and £100; and diffuse if >100 cells
were positive. In statistical calculations, positive reactions
of both markers also were considered as positive or negative.
Hybrid Capture II and PCR in LBC Medium
The Hybrid Capture II (HC2) assay was performed ac-
cording to the instructions of the manufacturer (Digene
Co., Gaithersburg, MD). In estimation of positive reac-
tions, samples were considered positive if the relative
light units cutoff (RLU/CO) were>1 (24). Only high-risk
HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
and 68) were tested. The method of PCR in LBC medium
(Universal Collection Medium, Digene Co.) has been de-
scribed previously (22). In brief, DNA purification was
performed with GFX (Genomic Blood DNA Purifica-
tion Kit, Amersham cat #27-9603-01, Piscataway, NJ)
and PCR amplification was performed with AmpliTaq
Gold DNA polymerase (Applied Biosystems, Foster City,
CA). PGMY09/11 L1 consensus primers to detect HPV
and GH20/PCO4 primers for human b-globin were
co-amplified.
FIG. 1. Positive nuclear and cytoplasmic immunoreaction for p16INK4A
is observed in metaplastic and glandular cells (3400).
FIG. 2. Positive nuclear immunoreaction for Ki67 is observed in reac-
tive squamous cells (3400).
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Statistical Analysis
Statistical analyses were performed using the SPSS (for
Windows, version 11.5) software package (SPSS, Chica-
go, IL), and the tables of frequencies were analyzed with
the chi-square test, with a likelihood ratio used to assess
the significance between the categorical variables. HPV
status was considered positive if HC2 and/or PCR were
positive.
RESULTS
The LBC slides from 156 patients were classified cy-
tologically negative and 43 as ASC-US. Only one case
was insufficient for technical problems. The number of
cells was sufficient (at least 5,000 cells as recommended
by TBS 2001) and well preserved (25). p16 immunostain-
ing was localized both in the nucleus and cytoplasm (Fig.
1). According to recent reports, both nuclear and cyto-
plasmic staining was considered positive (26). Only nu-
clear reaction for Ki-67 was observed (Fig. 2).
Table 1 shows the correlation between p16 and Ki67
staining in both HPV-negative and HPV-positive, cyto-
logically negative smears. Among these negative cyto-
logic samples, 101 were HPV-positive and 55 HPV-
negative. Of the HPV-positive group, 59 of 101 cases
(58.4%) were positive for both p16 and Ki67 immunos-
taining, and 17 of 101 (16.8%) were negative for both.
The proportion of Ki-67 positivity increased almost in
parallel with the increasing grade of p16 positivity
(p = 0.0001 for linear trend). In the HPV-negative group,
both markers were negative in 41 of 55 cases (74.5%).
Not unexpectedly, only 3 of 55 (5.4%) cytologically
negative smears were simultaneously positive for both
markers. No statistical relationship was observed between
the grade of p16 positivity and Ki-67 expression in this
HPV-negative group (chi-square, Pearson, p = 0.595).
The same correlation of marker expression in ASC-US
(equivocal) smears is depicted in Table 2. HPV-positive
ASC-US samples demonstrated a simultaneous positive
reaction for p16 and Ki67 in 11 of 16 cases (68.7%),
whereas 3 (18.7%) were concurrently negative. The re-
lationship between the two markers was of borderline sig-
nificance (chi-square, Pearson, p=0.053), but no linear
relationship was found between graded p16 and Ki-67
expression (p = 0.065 for linear trend). In the HPV-
negative ASC-US group, 7 of 27 cases (25.9%) cases were
completely negative, and 9 (33.3%) were positive for
both markers. In this group, there was no statistical asso-
ciation between the graded p16 and Ki-67 positivity (chi-
square, Pearson, p = 0.281).
In Table 3, a quantified Ki-67 expression is related to
p16 expression and HPV status in cytologically normal
smears. In HPV-positive group, the proportion of p16
positivity increased in parallel with the increasing grade
TABLE 1. Quantified p16 expression related to Ki-67 expression and HPV status in cytologically normal LBC smears
HPV positive HPV negative
p16 immunostaining Ki-67 negative Ki-67 positive Total Ki-67 negative Ki-67 positive Total
0 17 (16.8) 15 (14.8) 32 (31.7) 41 (74.5) 8 (14.5) 49 (89.1)
‡1 and £10 3 (2.9) 7 (6.9) 10 (9.9) 0 (0) 0 (0) 0
>10 and £50 4 (3.9) 31 (30.7) 35 (34.6) 2 (3.6) 1 (1.8) 3 (5.4)
>50 and £100 2 (1.9) 9 (8.9) 11 (10.9) 2 (3.6) 1 (1.8) 3 (5.4)
>100 1 (0.9) 12 (92.3) 13 (12.8) 0 (0) 0 (0) 0
Total 27 (26.7) 74 (73.3) 101 (100) 45 (81.7) 10 (18.2) 55 (100)
HPV, human papillomavirus; LBC, liquid-based cytology.
Data are numbers with percentages in parentheses.
TABLE 2. Quantified p16 expression related to Ki-67 expression and HPV status in cytologically equivocal (ASC-US) LBC smears
HPV positive HPV negative
p16 immunostaining Ki 67 negative Ki 67 positive Total Ki 67 negative Ki67 positive Total
0 3 (18.7) 1 (6.2) 4 (25) 7 (25.9) 7 (25.9) 14 (52)
‡1 and £10 0 (0.0) 1 (6.2) 1 (6.2) 0 (0) 0 (0) 0 (0)
>10 and £50 0 (0.0) 7 (43.7) 7 (43.7) 5 (18.5) 4 (14.8) 9 (33.3)
>50 and £100 1 (6.2) 1 (6.2) 2 (12.5) 0 (0.0) 2 (7.4) 2 (7.4)
>100 0 (0.0) 2 (12.5) 2 (12.5) 0 (0.0) 2 (7.4) 2 (7.4)
Total 4 (25) 12 (75) 16 (100) 12 (44.4) 15 (55.5) 27 (100)
HPV, human papillomavirus; LBC, liquid-based cytology; ASC-US, atypical squamous cells of undetermined significance.
Data are numbers with percentage in parentheses.
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of Ki-67-positivity (chi-square, Pearson, p = 0.001, and
p = 0.0001 for linear trend). Among HPV-negative sam-
ples, no statistical association could be established be-
tween graded Ki-67 expression and p16 positivity
(Pearson, p = 0.284).
Table 4 gives the same data for ASC-US smears. In
HPV-positive group, the proportion of p16 positivity in-
creased in parallel with the increasing grade of Ki-67 pos-
itivity, albeit the two highest categories are missing (chi-
square, Pearson, p = 0.026, and p = 0.018 for linear trend).
In the HPV-negative group, there was no statistical rela-
tionship between the grade of Ki-67 expression and p16
positivity (Pearson, p = 0.636).
After 12 months of follow-up of the ASC-US patients,
6 women still displayed ASC-US smear, of which 4 of 6
were HPV-positive and expressed both p16 and Ki-67
markers. Two of 43 (4.6%) ASC-US smears had high-
grade squamous intraepithelial lesions (HSIL) diagnosed,
and 1 (2.3%) had a low-grade squamous intraepithelial
lesion (LSIL). All of those were positive for HPV, p16,
and Ki-67.
DISCUSSION
The HPV infection by the high-risk types might iden-
tify women who are at increased risk for development of
a significant cervical lesion and, conversely, a negative
HPV test has a high negative predictive value. This po-
tential risk of developing a cervical lesion does not
necessarily mean that HPV infection would progress
(2). The use of p16 marker has been suggested to com-
pensate this lack of specificity of an HPV test, and advo-
cated as an adjunct tool in routine use, because it is
overexpressed in cases in which E7 oncogenes block
the activity of pRB that regulates p16 (5). For this reason,
the pivotal work of Klaes and colleagues (5) was crucial
to determinate the importance of p16 overexpression as
a specific markers for malignant and premalignant lesions
of the cervix in both histologic and cytologic samples.
These authors observed that p16INK4A is expressed in
dysplastic but not in normal cells. Moreover, low-grade
abnormalities testing positive for low-risk HPV did not
express detectable overexpression of p16INK4A.
The intention of our work was to observe whether the
p16 overexpression can occur in cases that are cytolog-
ically negative or equivocal (ASC-US), but test positive
for high-risk HPV. We wanted to test our hypothesis that
p16INK4A overexpression can be present in cytologic sam-
ples before any morphologic abnormalities are detect-
able. Conversely to some previous reports (5,26), we
could detect p16INK4A immunostaining in normal-looking
cervical cells. There are several recent reports on similar
findings (27–29). Interestingly, Sahebali and colleagues
(29) have found a close correlation between the numbers
TABLE 3. Quantified Ki-67 expression related to p16 expression and HPV status in cytologically normal LBC smears
HPV positive HPV negative
Ki67 immunostaining p16 negative p16 positive Total p16 negative p16 positive Total
0 17 (16.8) 10 (9.9) 27 (26.7) 41 (74.5) 3 (5.4) 44 (80)
‡1 and £10 12 (11.9) 40 (39.6) 52 (51.4) 7 (12.7) 1 (1.8) 8 (14.5)
>10 and £50 2 (1.9) 18 (17.8) 20 (19.8) 2 (3.6) 1 (1.8) 3 (5.4)
>50 and £100 0 (0) 1 (0.9) 1 (0.9) 0 (0) 0 (0) 0
>100 0 (0) 1 (0.9) 1 (0.9) 0 (0) 0 (0) 0
Total 31 (30.7) 70 (69.3) 101 (100) 49 (89.1) 6 (10.9) 55 (100)
HPV, human papillomavirus; LBC, liquid-based cytology.
Data are numbers with percentages in parentheses.
TABLE 4. Quantified Ki-67 expression related to p16 expression and HPV status in cytologically equivocal (ASC-US) LBC smears
HPV positive HPV negative
Ki67 immunostaining p16 negative p16 positive Total p16 negative p16 positive Total
0 3 (18.7) 1 (6.2) 4 (25) 7 (25.9) 4 (14.8) 11 (40.7)
‡1 and £10 1 (6.2) 7 (43.7) 8 (50) 6 (46.2) 7 (25.9) 13 (48.1)
>10 and £50 0 (0.0) 4 (25) 4 (25) 2 (7.4) 1 (3.7) 3 (11.1)
>50 and £100 0 (0.0) 0 (0.0) 0 0 (0.0) 0 (0.0) 0 (0.0)
>100 0 (0.0) 0 (0.0) 0 0 (0.0) 0 (0.0) 0 (0.0)
Total 4 (25) 12 (75) 16 (100) 15 (55.5) 12 (44.4) 27 (100)
HPV, human papillomavirus; LBC, liquid-based cytology; ASC-US, atypical squamous cells of undetermined significance.
Data are number with percentages in parentheses.
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of p16-stained cells and the HPV type, being most intense
in HPV16 type and lowest in low-risk HPV lesions. They
also reported that this correlation is also a significant
diagnostic sign, with higher mean count of p16-positive
reactions detectable in HSIL than in other diagnostic cat-
egories.
As we principally studied cytologically negative cases,
we used Ki67 proliferation marker to disclose an eventual
correlation between the insensitivity of p16 immunos-
taining and the expression of this cell cycle marker.
We observed that the majority of the cases concurrently
positive for both p16 and Ki67 markers occurred in the
group of patients testing positive for high-risk HPV. The
mean count of p16 immunoreactive cells falls between 10
and 50 of 1,000 cells, whereas that of Ki67-positive cells
were predominantly between 1 and 10 of 1,000 cells. The
value of Ki67 as a predictor in cervical lesions seems to
depend on the number of positive cells counted (19). As
an independent variable, Ki67 has a strong predictive val-
ue for progression for cervical intraepithelial neoplasia
(CIN) 1 and CIN 2 lesions (30). Similarly, there seems
to be a significant correlation between p16 and Ki67 im-
munoreactions among significant lesions (20). This is
consonant with the present observations, in which the
proportion of Ki-67 positivity increased almost in parallel
with the increasing grade of p16 positivity (p = 0.0001 for
linear trend). Furthermore, in our HPV-positive group, 59
of 101 cases (58.4%) were positive for both p16 and Ki67
immunostaining, whereas only 17 of 101 (16.8%) were
negative for both.
Whether the combination of p16 and Ki67 would be
useful as an adjunct tool to predict the development of
CIN lesions in women with normal or equivocal cytology
remains to be seen by the follow-up of our patients. They
all are under strict surveillance and attend the control vis-
its regularly. Among the women with ASC-US cytology
at the onset, we have already detected three cases with
significant lesions: two HSIL, and one case of LSIL. Sim-
ilarly, among the cases cytologically classified as nega-
tive, one case (positive for HPV by biomolecular assay)
revealed at cytologic examination slight atypias classified
as ASC-US after 36 months of follow-up.
As stated earlier, the rationale for the use of the p16 in
cervical pathology examination is based on the increasing
expression of viral oncogenes in dysplastic cells reflected
by the increased expression of p16INK4A. The potential
use of p16INK4A in routine cytology certainly depends
on additional long-term studies, including molecular test-
ing for high-risk HPV. The main unanswered questions in
our study are 1) whether all high-risk HPV-positive, cy-
tologically negative or equivocal, patients who express
p16INK4A and Ki67 will eventually develop cervical
lesion, and 2) whether such women with ASC-US cytol-
ogy will progress for a squamous intraepithelial lesion.
The three detected cases of squamous intraepithelial le-
sions among these women suggest that this might be the
case, and using these potential predictors might be seri-
ously considered in the management of patients with
equivocal cytology.
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